Antiphospholipid Antibody Induced by Nivolumab
نویسندگان
چکیده
Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma. It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab. Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including α-interferon and interleukin-2. We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma. The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive. The patient was treated with prednisone but, unfortunately, he expired a few days later.
منابع مشابه
Pyoderma gangrenosum in a patient with antiphospholipid antibody negative systemic lupus erythematosus: A case report
In any description of leg ulcers in systemic lupus erythematosus (SLE), pyoderma gangrenosum (PG) earns a mention at least for its being quite rare in such patients. The causative role of aPL (antiphospholipid antibody) in dermatological manifestations of SLE is undermined by the occurrence of PG in aPL negative SLE patients. To the best of our knowledge, there are only two reports of PG in aPL...
متن کاملComparison of Antiphospholipid Antibodies between Preeclamptsia and Normal Pregnant Women
Antiphospholipid antibodies (APLA) may be detected in normal pregnancies and also may cause thrombosis, recurrent fetal loss, placental infarction and preeclampsia. In the present study the possible differences in APLA titer between healthy pregnant women and preeclampsia cases without history of thrombosis was examined. The APLA titer in 50 healthy pregnant women with 50 preeclampsia cases wit...
متن کاملHigh incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
BACKGROUND Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), including pneumonitis. CASE PRESENTATION We present a case series of four patients with malignant ...
متن کاملBi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus
BACKGROUND Anti-programmed cell death 1 antibody nivolumab is a promising agent for various cancers. Immune-related adverse events are recognized; however, bi-cytopenia with nivolumab has not been reported. CASE PRESENTATION A 73-year-old man was diagnosed with advanced primary malignant melanoma of the esophagus with liver, lung, and lymph node metastases. Previous therapies including dacarb...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2018 شماره
صفحات -
تاریخ انتشار 2018